AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
AstraZeneca PLC News & Analysis
markets
What are emerging and frontier markets?
Power blocs, frontier stocks and investor shocks explained as the world becomes more complex
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,057.60 | 48.70 | -0.53% |
CAC 40 | 7,849.13 | 22.89 | -0.29% |
DAX 40 | 23,576.39 | 34.94 | -0.15% |
Dow JONES (US) | 46,292.78 | 88.76 | -0.19% |
FTSE 100 | 9,208.03 | 15.29 | -0.17% |
HKSE | 26,518.65 | 359.53 | 1.37% |
NASDAQ | 22,573.47 | 215.50 | -0.95% |
Nikkei 225 | 45,630.31 | 136.65 | 0.30% |
NZX 50 Index | 13,181.31 | 44.77 | 0.34% |
S&P 500 | 6,656.92 | 36.83 | -0.55% |
S&P/ASX 200 | 8,764.50 | 50.50 | -0.57% |
SSE Composite Index | 3,853.64 | 31.81 | 0.83% |